*Division of Nephrology and Transplantation, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands;

†Erasmus MC Transplant Institute , Rotterdam, the Netherlands;

‡Department of Hospital Pharmacy, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands;

§Rotterdam Clinical Pharmacometrics Group, Rotterdam, the Netherlands;

¶Department of Hospital Pharmacy, Meander Medical Center, Amersfoort, the Netherlands;

‖Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands; and

**InsightRX, San Francisco, California.

Correspondence: Marith I. Francke, BSc, Division of Nephrology and Renal Transplantation, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Room Rg-527, P.O. Box 2040, 3000 CA, Rotterdam, the Netherlands (e-mail: [email protected]).

D. A. Hesselink has received grant support, paid to his institution, from Astellas Pharma, Chiesi Farmaceutici SpA, and Bristol Myers-Squibb, as well as lecture and consulting fees from Astellas Pharma, Chiesi Farmaceutici SpA, Novartis Pharma, and Vifor Pharma, over the past 3 years. R. J. Keizer is a stockholder and employee of InsightRX, a precision dosing software company. T. van Gelder received lecture fees and study grants from Chiesi and Astellas, in addition to consulting fees from Roche Diagnostics, Thermo Fisher, Vitaeris, CSL Behring, Astellas, and Aurinia Pharma. T. van Gelder neither has employment nor stock ownership at any of these companies, he does not have patents or patent applications. All other authors declare no conflicts of interest.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.drug-monitoring.com).